ERBB2 and breast carcinoma: This pre-clinical study suggests that the combination of neratinib and dasatinib is a highly promising novel therapeutic strategy for HER2+ breast cancer, particularly tumors that are innately resistant or have acquired resistance to current HER2-targeted therapies.